Literature DB >> 22592405

Physical and functional interaction between the ID1 and p65 for activation of NF-κB.

Xiao Peng1, Yuna Wang, Swapna Kolli, Junpeng Deng, Li Li, Zhixin Wang, J Usha Raj, Deming Gou.   

Abstract

Inhibitor of differentiation or DNA binding-1 (ID1) is an important helix-loop-helix (HLH) transcription factor involved in diverse biological functions including cell differentiation, proliferation, apoptosis, and senescence. Recently, it was reported that ID1 can activate the NF-κB signaling pathway in a variety of cancer cells and a T cell line, but the mechanisms involved in ID1-mediated transactivation of NF-κB are not clear. In this study, we demonstrate by both in vitro pull-down assays and a cell-based in vivo two-hybrid system that ID1-mediated NF-κB activation is due to its physical interaction with p65. We have identified that the transcriptional activation domain (TAD) in p65 and the HLH domain in ID1 are vital for their interaction. Interestingly, a single site mutation (Leu76) in the HLH domain of ID1 protein drastically decreased its ability to bind with p65. Using a dual-luciferase assay, we demonstrated that the interaction between ID1 and p65 modulates activation of the NF-κB signaling pathway in vivo. In addition, we demonstrated that, by affecting the nuclear translocation of p65, ID1 is essential in regulating TNF-α-induced p65 recruitment to its downstream target, the cellular inhibitor of apoptosis protein 2 (cIAP2) promoter.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592405      PMCID: PMC3423031          DOI: 10.1152/ajpcell.00365.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  50 in total

1.  Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.

Authors:  Hiu Wing Cheung; Ming-tat Ling; Sai Wah Tsao; Y C Wong; Xianghong Wang
Journal:  Carcinogenesis       Date:  2004-01-23       Impact factor: 4.944

2.  Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells.

Authors:  Ming-Tat Ling; Xianghong Wang; Xue-Song Ouyang; Kexin Xu; Sai-Wah Tsao; Yong-Chuan Wong
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

Review 3.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Authors:  C Q Lin; J Singh; K Murata; Y Itahana; S Parrinello; S H Liang; C E Gillett; J Campisi; P Y Desprez
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

5.  Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis.

Authors:  H Maruyama; J Kleeff; S Wildi; H Friess; M W Büchler; M A Israel; M Korc
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.

Authors:  Monika Schindl; Sebastian F Schoppmann; Thomas Ströbel; Harald Heinzl; Christina Leisser; Reinhard Horvat; Peter Birner
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

7.  Id1 promotes tumor cell migration in nonsmall cell lung cancers.

Authors:  Raka Bhattacharya; Jeanne Kowalski; Allison R Larson; Malcolm Brock; Rhoda M Alani
Journal:  J Oncol       Date:  2010-04-18       Impact factor: 4.375

8.  Annexin A2 interactions with Rab14 in alveolar type II cells.

Authors:  Deming Gou; Amarjit Mishra; Tingting Weng; Lijing Su; Narendranath Reddy Chintagari; Zhixin Wang; Honghao Zhang; Li Gao; Pengcheng Wang; Heidi M Stricker; Lin Liu
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

9.  High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.

Authors:  Ruoping Tang; Pierre Hirsch; Fanny Fava; Simona Lapusan; Christophe Marzac; Irène Teyssandier; Julia Pardo; Jean-Pierre Marie; Ollivier Legrand
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

10.  Inhibitor of differentiation 1 (Id1) expression attenuates the degree of TiO2-induced cytotoxicity in H1299 non-small cell lung cancer cells.

Authors:  Young Sook Lee; Seokjoo Yoon; Hea Jin Yoon; Kyuhong Lee; Hyoun Kyoung Yoon; Jeung-Hoon Lee; Chang Woo Song
Journal:  Toxicol Lett       Date:  2009-05-30       Impact factor: 4.372

View more
  5 in total

1.  Up-regulation of the Sirtuin 1 (Sirt1) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) genes in white adipose tissue of Id1 protein-deficient mice: implications in the protection against diet and age-induced glucose intolerance.

Authors:  Ying Zhao; Flora Ling; Timothy M Griffin; Ting He; Rheal Towner; Hong Ruan; Xiao-Hong Sun
Journal:  J Biol Chem       Date:  2014-09-04       Impact factor: 5.157

2.  Id-1 Promotes Reendothelialization In The Early Phase After Vascular Injury Through Activation Of NFkB/survivin Signaling Pathway.

Authors:  Wei Li; Dayong Du; Yuntian Li
Journal:  Drug Des Devel Ther       Date:  2019-10-31       Impact factor: 4.162

3.  Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma.

Authors:  Stefan Nagel; Claudia Pommerenke; Hilmar Quentmeier; Corinna Meyer; Maren Kaufmann; Roderick A F MacLeod
Journal:  Biomedicines       Date:  2022-08-21

4.  Cellular inhibitor of apoptosis-2 is a critical regulator of apoptosis in airway epithelial cells treated with asthma-related inflammatory cytokines.

Authors:  Eugene Roscioli; Rhys Hamon; Richard E Ruffin; Susan Lester; Peter Zalewski
Journal:  Physiol Rep       Date:  2013-10-11

5.  Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death.

Authors:  Dave J Augeri; Elaine Langenfeld; Monica Castle; John A Gilleran; John Langenfeld
Journal:  Mol Cancer       Date:  2016-04-06       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.